21Feb 2017

SERUM GALECTIN-4 (GAL-4) IN PATIENTS WITH GASTRIC ADENOCARCINOMA: ACTIVE PLAYER IN THE FIELD.

  • Department of Internal Medicine, Faculty of Medicine, Zagazig University, Egypt.
  • Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Introduction: Galectin-4 is one of a ?-galactosides binding proteins family that recognize a variety of glycan–containing proteins at the cell surface and are overexpressed in various tumors, including gastric cancer. Galectin-4 overexpression as well as changes in their subcellular distribution has been associated with gastric cancer progression and poor prognosis. It may provide diagnostic molecular markers for gastric cancer as well as clues for developing therapeutic targets on individual basis. Aim of the study: To detect the levels of GAL-4 in the sera of healthy people and patients with gastric cancer and also, to investigate the validity of using GAL-4 as a specific diagnostic marker of gastric cancer. Patients and methods: 25 gastric cancer patients were included in this study. They were among patients who attending the Endoscopy Department, during the period from September 2015 to March 2016. In addition, 15 apparently healthy people were chosen as a healthy control group. For these two groups, serum level of GAL-4 using ELISA technique was carried out. Results: There was a statistically significant difference in serum level of GAL-4 among gastric adenocarcinoma patients in comparison to healthy controls (p ? 0.001), using receiver operating characteristic curve (ROC) area, serum GAL-4 has high area under the curve (0.924) with a cut off value equal to or above 0.42ng/ml which was associated with the highest sensitivity (100%). Conclusions: Serum levels of GAL-4 were significantly higher in patients with malignant gastric adenocarcinoma which may confirm a possible role of this marker in the pathogenesis of the disease, furthermore the highest sensitivity and best accuracy obtained from serum GAL-4 was by using a cut off values equal to or above 0.42ng/ml. So, GAL-4 may be promising new diagnostic tools especially at early stages and among patients at high risk.


  1. Neugut, A. I., Hayek, M., and Howe, G. (1996); Epidemiology 1. of gastric cancer. Semin. Oncol. 23: 281–291.
  2. Werner, M., Becker, K. F., Keller, G., and Hofler, H. (2001); 2. Gastric adenocarcinoma: pathomorphology and molecular pathology. J. Cancer Res. Clin. Oncol. 127: 207– 216.
  3. Kim B., Bang S., Lee S., et al., (2003); Expression Profiling 3. and Subtype-Specific Expression of Stomach Cancer. Cancer Res; 63: 8248-8255.
  4. ACCC (2012); Gastric Cancer Quick Facts, Association of 4. Community cancer centers, http://www.accc-cancer.org/education/GastricCancer-Facts.asp.
  5. American Cancer Society: Cancer Facts and Figures 5. (2013); Atlanta, Ga: American Cancer Society, 2013.http://www.cancer.gov/cancertopics/pdq/prevention/gastric/HealthProfessional/page2#Reference2.5.
  6. Barondes SH, Castronovo V, Cooper DNW, Cummings RD, 6. Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Ken-ichi K, Leffler H, Liu FT, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PWJ, Rini JM, Wang JL (1994); Galectins: a family of animal ?-galactoside-binding lectins. Cell; 76:597–598.
  7. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F (2004); 7. Introduction to Galectins, Glycoconjugate Journal; 19:433-440.
  8. Balan V, Makker P N, RAZ A (2010); Galectins as Cancer 8. Biomarkers, Cancers, 2, 592-610.
  9. Rabinovich G A, Toscano M A, Ilarregui J M, Rubinstein 9. N (2004); Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses. Glycoconj J; 19: 565–573.
  10. Young A R, Meeusen E N (2004); Galectins in parasite 10. Infection and allergic inflammation, Glycoconjugate journal; 19: 601-606.
  11. Nakahara S, Oka N, Raz A (2005); on the role of galectin-3 11. in cancer apoptosis. Apoptosis; 10:267-275.
  12. Rabinovich G A, 12. Liu FT, Hirashima M, Anderson A (2007) an emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol; 66:143-158.
  13. Liu F T, Rabinovich GA (2005); Galectins as modulators of tumor progression. Nat Rev Cancer; 5:29-41.
  14. Antibodies – online. com:   GALECTIN 4 (GAL-4) ELISA KIT. http://www.antibodies-online.com/
  15. Sorlie DE. (1995); Medical biostatistics and epidemiology: Examination and Board review. First ed, Norwalk, Connecticut, Appleton and Lange: 47 – 88.
  16. Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, Chen C, Rhodes JM, Yu LG (2011); Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium. Clin Cancer Res.; 17(22):7035-46.
  17. Dumic J, Dabelic S, Flogel M (2006); Galectin-3: An open-ended story. Biochim Biophys Acta.; 1760: 616-635.
  18. Nangia-Makker P, Ochieng J, Christman JK, Raz A (1993); Regulation of the expression of galactoside-binding lectin during human monocytic differentiation. Cancer Res.; 53: 5033-7.
  19. Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ (2001); Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol; 69:555-64.
  20. Miles FL, Pruitt FL, van Golen KL, Cooper CR (2008); 20. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis.; 25: 305-24.
  21. Duckworth CA, Yu LG (2012); Galectins and disease 21. Implications for targeted therapeutics in: Galectins in the blood circulation: potential therapeutic targets of cancer metastasis. ACS Symposium series, American Chemical Society: Washington. Chapter 18, pp. 309–322.

[Ahmed Hamouda Arnaout and Lamya Mahmoud Ibrahim. (2017); SERUM GALECTIN-4 (GAL-4) IN PATIENTS WITH GASTRIC ADENOCARCINOMA: ACTIVE PLAYER IN THE FIELD. Int. J. of Adv. Res. 5 (Feb). 1162-1167] (ISSN 2320-5407). www.journalijar.com


Ahmed Hamouda Arnaout
Department of Internal Medicine, Faculty of Medicine, Zagazig University, Egypt.

DOI:


Article DOI: 10.21474/IJAR01/3269      
DOI URL: http://dx.doi.org/10.21474/IJAR01/3269